AVM Biotechnology Analysis: $16M Raised
What is AVM Biotechnology?
AVM Biotechnology develops AVM0703, a proprietary high-dose dexamethasone formulation that triggers the release of endogenous gamma delta TCR+ invariant TCR+ bispecific T lymphocytes and Natural Killer T cells. These immune cells are activated rapidly after a single dose and show promise in treating no-option cancers, autoimmunity, and infectious diseases. The company was founded by Dr. Theresa Deisher with a mission to defeat cancer and is recognized as a 2024 NIH Innovation Company and 2023 NCI Showcase Company.
Location
Seattle, United States
Employees
11-50
Founded
2008
Product Features & Capabilities
- AVM0703 formulation at supra-pharmacologic doses
- Activation of endogenous gamma delta TCR+ invariant TCR+ bispecific T lymphocytes
- Production and release of Natural Killer T-like immune cells
- Rapid immune response within hours of dosing
- Pre-clinical and clinical data supporting efficacy in cancer and autoimmunity
Use Cases
Treat patients with no-option cancer therapies using AVM0703; Administer AVM0703 to patients with autoimmune syndromes; Provide compassionate use access for rare or severe conditions; Conduct clinical trials for gamma delta TCR+ T lymphocytes in mixed phenotype AML; Monitor immune cell response following single-dose administration
How much AVM Biotechnology raised
Funding - $16M
Other Considerations
Recognized as 2024 NIH Innovation Company; Named 2023 NCI Showcase Company; Recognized as 2022 NIH/NIDDK Showcase Company; Founded by Dr. Theresa Deisher; Pre-clinical and clinical data support immune cell activation in cancer and autoimmunity; Active clinical trials for mixed phenotype AML and infectious diseases
See something that needs updating? Suggest edits to this profile.